CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Hepatocellular Carcinoma
Conditions
Advanced Hepatocellular Carcinoma, Liver Cancer, Hepatic Cancer, Liver Neoplasms
Trial Timeline
Jul 9, 2010 → Sep 9, 2013
NCT ID
NCT01033240About CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kg
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kg is a phase 2 stage product being developed by Daiichi Sankyo for Advanced Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01033240. Target conditions include Advanced Hepatocellular Carcinoma, Liver Cancer, Hepatic Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01033240 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Hepatocellular Carcinoma